SBC-102 in patients with liver dysfunction due to LAL deficiency

• Register: EUCTR
• Last refreshed on: 18 September 2012
• Main ID: EUCTR2010-024068-16-GB
• Date of registration: 10/01/2011
• Prospective Registration: Yes
• Primary sponsor: Synageva Biopharma Corp.
• Public title: SBC-102 in patients with liver dysfunction due to LAL deficiency
• Scientific title: An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency. - SBC-102 in patients with liver dysfunction due to LAL deficiency
• Date of first enrolment: 08/03/2011
• Target sample size: 9
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024068-16
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no

Countries of recruitment

Czech Republic, United Kingdom

Contacts

• Name: Sophie Bark-Jones
• Affiliation: Premier Research Group Ltd.

• Name: Sophie Bark-Jones
• Affiliation: Premier Research Group Ltd.

Key inclusion & exclusion criteria

Inclusion criteria:
1. Patient understands the full nature and purpose of the study, including possible risks and side effects, and is willing and able to comply with all study procedures and provide informed consent 2. Male or female patients = 18 years = 65 years of age 3. Documented decreased LAL activity relative to the normal range of the lab performing the assay or documented result of molecular genetic testing confirming diagnosis of LAL deficiency 4. Evidence of liver involvement based on clinical presentation and/or laboratory test results (ALT or AST = 1.5xULN) 5. If on a statin or ezetimibe, must be on a stable dose for at least 4 weeks prior to screening 6. All women must have negative serum pregnancy test at screening and cannot be breast feeding 7. Female subjects of childbearing potential must agree to use a highly effective and approved contraceptive method(s) for the duration of the study and continue to use for 30 days after last dose of study drug. A highly effective method of contraception is defined as: a. strict abstinence; b. bilateral tubal ligation; c. combined oral contraceptives (estrogens and progesterone), implanted or injectable contraceptives on a stable dose for at least 1 month prior to the Screening visit; d. hormonal intra uterine device (IUD) inserted at least 1 month prior to the Screening visit; e. vasectomized partner for at least 3 months prior to the Screening visit. Male subjects, and their partners must be using, and continue to use for 30 days after last dose of study drug, an acceptable method of birth control. Women considered not of childbearing potential must be surgically sterile (total hysterectomy, bilateral salpingo-oophorectomy) or post-menopausal, which is defined as a complete cessation of menstruation for at least one year after the age of 45 years.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion criteria:
1. Clinically significant concurrent disease, serious inter-current illness, concomitant medications or other extenuating circumstances that, in the opinion of the Investigator, would either interfere with study participation or the interpretation of the effects of SBC-102. 2. Clinically significant abnormal values on laboratory screening tests, other than liver function or lipid panel tests. Subjects with an abnormal laboratory value that is of borderline significance may be allowed to undergo repeat testing once within a 30 day period. 3. Patient has participated in a study employing an investigational drug within 30 days of the screening 4. Child-Pugh Class C or AST and/or ALT persistently elevated > 3xULN at screening (2 or more occasions) 5. Previous hemopoietic bone marrow or liver transplant 6. Patient has received prior treatment with enzyme replacement therapy 7. Subject has a total score of 8 or more on a screening Alcohol Use Disorders Identification Test (AUDIT) 8. Patients with known hypersensitivity to eggs


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare disorder, with an estimated prevalence of less than 0.2 lives per 100,000. Although a single disease, LAL Deficiency has two phenotypes, Cholesteryl Ester Storage Disease (CESD) and Wolman Disease (WD). Both forms of the disease lead to the accumulation of fats, in various tissues and cell types.
MedDRA version: 14.0 Level: SOC Classification code 10027433 Term: Metabolism and nutrition disorders System Organ Class: 10027433 - Metabolism and nutrition disorders
MedDRA version: 14.0 Level: HLGT Classification code 10021605 Term: Inborn errors of metabolism System Organ Class: 10027433 - Metabolism and nutrition disorders
MedDRA version: 14.0 Level: HLT Classification code 10024579 Term: Lysosomal storage disorders System Organ Class: 10010331 - Congenital, familial and genetic disorders

Intervention(s)

Product Name: recombinant human lysosomal acid lipase (rhLAL)
Product Code: SBC-102
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: not available
Current Sponsor code: SBC-102
Other descriptive name: recombinant human lysosomal acid lipase (rhLAL)
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2-

Primary Outcome(s)

Secondary Objective: The secondary objective is to characterise the pharmacokinetics of SBC-102 delivered by intravenous infusion after single and multiple doses [pre and post infusion Day 0 and 21].

Timepoint(s) of evaluation of this end point: At study visits.

Main Objective: The primary objective of the study is to evaluate the safety and tolerability of SBC-102 in patients with liver dysfunction due to LAL deficiency (vital signs, physical examination, clinical laboratory tests, immunogenicity tests, adverse event assessment, concomitant medications).

Primary end point(s): The primary objective is to evaluate the safety and tolerability of SBC-102 in patients with liver dysfunction due to LAL deficiency.

Secondary Outcome(s)

Secondary end point(s): The secondary objective is to characterise the pharmacokinetics of SBC-102 delivered by IV infusion after single and multiple doses [pre and post infusion Day 0 and 21].

Secondary ID(s)

LAL-CL01